Gyroscope Therapeutics: Funding, Investors & Team (Sep 2026)
Gyroscope is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye. The company explores the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD), and gene therapy as a mode of treatment delivery. Its lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing the production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and Phase II clinical trials called EXPLORE and HORIZON. Andrew Lotery, David Kavanagh, and Peter Lachmann co-founded Gyroscope Therapeutics in Stevenage, Herefordshire in 2016.
Gyroscope Therapeutics has raised $149M across 1 funding round on record, the most recent a Series C of $149M announced in Mar 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Gyroscope Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2021.
Gyroscope Therapeutics Funding Rounds
Gyroscope Therapeutics Founders and Leadership Team
Contact details for the Gyroscope Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Gyroscope Therapeutics Funding Compared to Other Biotechnology Startups
Gyroscope Therapeutics' latest round of $149M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Gyroscope Therapeutics in Biotechnology and Stevenage
Companies Similar to Gyroscope Therapeutics
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
Gyroscope Therapeutics Funding FAQs
What does Gyroscope Therapeutics do?
Gyroscope is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye. The company explores the convergence of advancements made in the understanding of the complement system’s impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD), and gene therapy as a mode of treatment delivery. Its lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. GT005 is designed to restore balance to an overactive complement system by increasing the production of the Complement Factor I protein. GT005 is currently being evaluated in a Phase I/II clinical trial called FOCUS and Phase II clinical trials called EXPLORE and HORIZON. Andrew Lotery, David Kavanagh, and Peter Lachmann co-founded Gyroscope Therapeutics in Stevenage, Herefordshire in 2016.
How much funding has Gyroscope Therapeutics raised?
Gyroscope Therapeutics has raised $149M across 1 round on record. The most recent is a Series C of $149M announced in Mar 2021.
When did Gyroscope Therapeutics last raise funding?
Gyroscope Therapeutics' most recent funding round on record is a Series C of $149M, announced in Mar 2021.
Who is the CEO of Gyroscope Therapeutics?
Khurem Farooq is listed as CEO at Gyroscope Therapeutics.
Where is Gyroscope Therapeutics headquartered?
Gyroscope Therapeutics is based in Stevenage, Herefordshire, United Kingdom.
How many employees does Gyroscope Therapeutics have?
Gyroscope Therapeutics is in the 101-250 employee band.
How does Gyroscope Therapeutics' funding compare to other Biotechnology startups?
Gyroscope Therapeutics' latest round of $149M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Gyroscope Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Gyroscope Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.